Back to results
US 2026/0297112 A1Published application
Ras inhibitors
AssigneeRevolution Medicines, Inc.
InventorsJohn E. KNOX, Elena S. KOLTUN, Dylan E. PARSONS, Aidan TOMLINSON, G. Leslie BURNETT, James GREGG, Adrian L. GILL, Andreas BUCKL
Life of this patent
Estimating the term…
Abstract
The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
Claims28
A compound of formula (A) or (B):
- or a salt thereof, wherein:
- n is 2;
- the R2 combine together with the atoms to which they are attached and any intervening atoms form an optionally substituted C4-C8 cycloalkyl;
- and
- Rx is C1-C6 alkyl.
2 more elements
A compound of the formula (A-2) or (B-2):
- or a salt thereof, wherein:
- n is 2;
- the R2 combine together with the atoms to which they are attached and any intervening atoms form an optionally substituted C4-C8 cycloalkyl;
- Rx is a C1-C6 alkyl;
- PNG is a nitrogen protecting group;
- X is halo;
- and
- A is optionally substituted C2-C4 alkylene, optionally substituted C1-C4 heteroalkylene, optionally substituted C2-C4 alkenylene, optionally substituted 3- to 6-membered cycloalkylene, optionally substituted 3- to 6-membered heterocycloalkylene, optionally substituted 6-membered arylene, or optionally substituted 5- to 10-membered heteroarylene.
5 more elements
Dependencies are inferred from the claim text.